Resilience Acquires Biologics CDMO Ology Bioservices

By Miranda Greenberg -

April 15, 2021

Resilience, a recently launched manufacturing and technology company for biologics and advanced therapies, has acquired Ology Bioservices, an Alachua, Florida-based biologics CDMO.

Resilience was launched in November 2020 with initial capital of $800 million with a specific focus on manufacturing innovation, including for new modalities. Its executive leadership includes Patrick Yang, Ph.D., Vice Chairman, Resilience, and former Executive Vice President and Global Head of Technical/Product Operations, Roche/Genentech, and Rahul Singhvi, Sc.D., CEO, and Director, and former Chief Operating Officer of Takeda’s Vaccine business, where he was responsible for worldwide vaccine CMC and manufacturing operations. Before Takeda, Dr. Singhvi was President and CEO of Novavax, a Gaithersburg, Maryland-based vaccine company, from 2005 to 2011.

Ology Bio’s drug-substance manufacturing capabilities include cell-and-gene therapies, live-viral vaccines and vectors, oncolytic viruses, plasmids, and monoclonal antibodies. With the acquisition, Resilience gains 300 employees and 200,000 square feet of manufacturing, office, process development, and quality assurance/quality control space across locations in Florida, California, and Maryland, with additional expansion projects underway.

The acquisition is Resilience’s third recent acquisition. Earlier this month (April 2021), Resilience acquired two commercial manufacturing facilities in North America, including a facility from Sanofi.

Source: Resilience